Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia […]
Category: BioUtah News
GE HealthCare’s Economic Impact Across Utah
GE HealthCare’s Economic Impact Across Utah […]
RefloDx Wins Trans Atlantic Angel Grand Prize
RefloDx Wins Trans Atlantic Angel Grand Prize. […]
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies […]
DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES […]
Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases. […]
Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
Strategic Expansion in Salt Lake City Headquarters Will Meet Stringent EU GMP Annex 1 Requirements […]
RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS […]
Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025
Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025 […]
Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
Groundbreaking Preclinical Data Propel Clinical Milestone […]
Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development […]
NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
DOMESTIC STABLE ISOTOPE PROGRAM KEY TO STABILIZING SUPPLY CHAINS, ENABLING INNOVATION […]